Summary of the third quarter (2022-01-01 - 2022-03-31)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,1 (-1,5)
-
Earnings per share*
SEK -0.06 (-0.10)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.
Summary of the nine-month period (2021-07-01 - 2021-12-31)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -3,2 (-4,6)
-
Earnings per share*
SEK -0.20 (-0.31) - Cash and cash equivalents at the end of the period amounted to MSEK 38,9 (3,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 16,225,200. For the comparison period, the average number of shares was 14,920,478.Amounts in brackets refer to the corresponding period last year.
CEO's comment
The clinical myeloma study with the Company's drug candidate OsteoDex, which was financed via a rights issue in
Our previous preclinical studies regarding the effect of OsteoDex on different myeloma cell cultures clearly show a strong tumor cell killing effect. Even compared to Melfalan, which is a proven standard preparation for the treatment of multiple myeloma (MM), the effect of OsteoDex is strikingly strong. Given the similarity in the skeletal disease process between MM and mCRPC and existing clinical experience, we have reason to be optimistic about the MM study's conditions to result in "proof of concept".
In April, the company convened an extraordinary general meeting on
Anders R Holmberg
CEO
Contact
This information is such information that
https://news.cision.com/dextech/r/dextech-medical-ab--interim-report-july-1--2021---march-31--2022,c3556969
https://mb.cision.com/Main/11652/3556969/1571985.pdf
(c) 2022 Cision. All rights reserved., source